Acute effects of resveratrol to enhance cocaine-induced dopamine neurotransmission in the striatum

Neuroscience Letters

Volumn 542, Issue , 2013, Pages 107-112

  Shuto, Takahide ^a,b   Kuroiwa, Mahomi ^a,b   Koga, Yuki ^a,c   Kawahara, Yukie ^a   Sotogaku, Naoki ^a,b   Toyomasu, Koji ^c   Nishi, Akinori ^a,b  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

^c KURUME UNIVERSITY   (Japan)

Author keywords

AMPK; CamKK ; Cocaine; DARPP 32; Dopamine; ERK; HDACs; MAO A; MAO B; Monoamine oxidase; NAD; PDE; PKA; Resveratrol; SDS; SIRT1; SIRT2; Striatum; TH

Indexed keywords

CLORGYLINE; COCAINE; DOPAMINE; DOPAMINE 1 RECEPTOR; PARGYLINE; PHOSPHOPROTEIN DARPP 32; RESVERATROL; TYROSINE 3 MONOOXYGENASE;

ARTICLE; BEHAVIOR; CORPUS STRIATUM; DRUG DEPENDENCE; DRUG INHIBITION; DRUG METABOLISM; LOCOMOTION; MALE; MOUSE; NEUROTRANSMISSION; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

ANIMALS; CENTRAL NERVOUS SYSTEM STIMULANTS; COCAINE; CYCLIC AMP-DEPENDENT PROTEIN KINASES; DOPAMINE; DOPAMINE AND CAMP-REGULATED PHOSPHOPROTEIN 32; ISOENZYMES; MALE; MICE; MICE, INBRED C57BL; MONOAMINE OXIDASE; MONOAMINE OXIDASE INHIBITORS; MOTOR ACTIVITY; NEOSTRIATUM; PHOSPHORYLATION; STILBENES; SYNAPTIC TRANSMISSION;

EID: 84876722719     PISSN: 03043940     EISSN: 18727972     Source Type: Journal    
DOI: 10.1016/j.neulet.2013.02.050     Document Type: Article

References (23)

1. Bateup H.S., Svenningsson P., Kuroiwa M., Gong S., Nishi A., Heintz N., Greengard P. Cell type-specific regulation of DARPP-32 phosphorylation by psychostimulant and antipsychotic drugs. Nat. Neurosci. 2008, 11:932-939.
2. Canto C., Auwerx J. Targeting sirtuin 1 to improve metabolism: all you need is NAD(+)?. Pharmacol. Rev. 2012, 64:166-187.
3. Chuang D.M., Leng Y., Marinova Z., Kim H.J., Chiu C.T. Multiple roles of HDAC inhibition in neurodegenerative conditions. Trends Neurosci. 2009, 32:591-601.
4. Donmez G. The neurobiology of sirtuins and their role in neurodegeneration. Trends Pharmacol. Sci. 2012, 33:494-501.
5. Donmez G., Wang D., Cohen D.E., Guarente L. SIRT1 suppresses beta-amyloid production by activating the alpha-secretase gene ADAM10. Cell 2010, 142:320-332.
6. Fukui R., Svenningsson P., Matsuishi T., Higashi H., Nairn A.C., Greengard P., Nishi A. Effect of methylphenidate on dopamine/DARPP signalling in adult, but not young, mice. J. Neurochem. 2003, 87:1391-1401.
7. Gao J., Wang W.Y., Mao Y.W., Graff J., Guan J.S., Pan L., Mak G., Kim D., Su S.C., Tsai L.H. A novel pathway regulates memory and plasticity via SIRT1 and miR-134. Nature 2010, 466:1105-1109.
8. Guarente L., Franklin H. Epstein lecture: sirtuins aging, and medicine. N. Engl. J. Med. 2011, 364:2235-2244.
9. Hu Y., Liu J., Wang J., Liu Q. The controversial links among calorie restriction, SIRT1, and resveratrol. Free Radic. Biol. Med. 2011, 51:250-256.
10. Knutson M.D., Leeuwenburgh C. Resveratrol and novel potent activators of SIRT1: effects on aging and age-related diseases. Nutr. Rev. 2008, 66:591-596.
11. Libert S., Pointer K., Bell E.L., Das A., Cohen D.E., Asara J.M., Kapur K., Bergmann S., Preisig M., Otowa T., Kendler K.S., Chen X., Hettema J.M., van den Oord E.J., Rubio J.P., Guarente L. SIRT1 activates MAO-A in the brain to mediate anxiety and exploratory drive. Cell 2011, 147:1459-1472.
12. Matos M.J., Vina D., Picciau C., Orallo F., Santana L., Uriarte E. Synthesis and evaluation of 6-methyl-3-phenylcoumarins as potent and selective MAO-B inhibitors. Bioorg. Med. Chem. Lett. 2009, 19:5053-5055.
13. McCahill A.C., Huston E., Li X., Houslay M.D. PDE4 associates with different scaffolding proteins: modulating interactions as treatment for certain diseases. Handb. Exp. Pharmacol. 2008, 186:125-166.
14. Milne J.C., Lambert P.D., Schenk S., Carney D.P., Smith J.J., Gagne D.J., Jin L., Boss O., Perni R.B., Vu C.B., Bemis J.E., Xie R., Disch J.S., Ng P.Y., Nunes J.J., Lynch A.V., Yang H., Galonek H., Israelian K., Choy W., Iffland A., Lavu S., Medvedik O., Sinclair D.A., Olefsky J.M., Jirousek M.R., Elliott P.J., Westphal C.H. Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature 2007, 450:712-716.
15. Nishi A., Kuroiwa M., Miller D.B., O'Callaghan J.P., Bateup H.S., Shuto T., Sotogaku N., Fukuda T., Heintz N., Greengard P., Snyder G.L. Distinct roles of PDE4 and PDE10A in the regulation of cAMP/PKA signaling in the striatum. J. Neurosci. 2008, 28:10460-10471.
16. Nishi A., Snyder G.L., Greengard P. Bidirectional regulation of DARPP-32 phosphorylation by dopamine. J. Neurosci. 1997, 17:8147-8155.
17. Park S.J., Ahmad F., Philp A., Baar K., Williams T., Luo H., Ke H., Rehmann H., Taussig R., Brown A.L., Kim M.K., Beaven M.A., Burgin A.B., Manganiello V., Chung J.H. Resveratrol ameliorates aging-related metabolic phenotypes by inhibiting cAMP phosphodiesterases. Cell 2012, 148:421-433.
18. Renthal W., Kumar A., Xiao G., Wilkinson M., Covington H.E., Maze I., Sikder D., Robison A.J., LaPlant Q., Dietz D.M., Russo S.J., Vialou V., Chakravarty S., Kodadek T.J., Stack A., Kabbaj M., Nestler E.J. Genome-wide analysis of chromatin regulation by cocaine reveals a role for sirtuins. Neuron 2009, 62:335-348.
19. Robison A.J., Nestler E.J. Transcriptional and epigenetic mechanisms of addiction. Nat. Rev. Neurosci. 2011, 12:623-637.
20. Schmitt K.C., Reith M.E. Regulation of the dopamine transporter: aspects relevant to psychostimulant drugs of abuse. Ann. N. Y. Acad. Sci. 2010, 1187:316-340.
21. Svenningsson P., Nishi A., Fisone G., Girault J.A., Nairn A.C., Greengard P. DARPP-32: an integrator of neurotransmission. Annu. Rev. Pharmacol. Toxicol. 2004, 44:269-296.
22. Xu Y., Wang Z., You W., Zhang X., Li S., Barish P.A., Vernon M.M., Du X., Li G., Pan J., Ogle W.O. Antidepressant-like effect of trans-resveratrol: involvement of serotonin and noradrenaline system. Eur. Neuropsychopharmacol. 2010, 20:405-413.
23. Yanez M., Fraiz N., Cano E., Orallo F. Inhibitory effects of cis- and trans-resveratrol on noradrenaline and 5-hydroxytryptamine uptake and on monoamine oxidase activity. Biochem. Biophys. Res. Commun. 2006, 344:688-695.